MNPR vs. KPRX, RDHL, AVTX, PIRS, PPBT, IMNN, HUGE, EDSA, ELAB, and AKTX
Should you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Kiora Pharmaceuticals (KPRX), RedHill Biopharma (RDHL), Avalo Therapeutics (AVTX), Pieris Pharmaceuticals (PIRS), Purple Biotech (PPBT), Imunon (IMNN), FSD Pharma (HUGE), Edesa Biotech (EDSA), Elevai Labs (ELAB), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical preparations" industry.
Monopar Therapeutics (NASDAQ:MNPR) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.
In the previous week, Monopar Therapeutics had 4 more articles in the media than Kiora Pharmaceuticals. MarketBeat recorded 11 mentions for Monopar Therapeutics and 7 mentions for Kiora Pharmaceuticals. Monopar Therapeutics' average media sentiment score of 0.57 beat Kiora Pharmaceuticals' score of 0.00 indicating that Monopar Therapeutics is being referred to more favorably in the media.
Monopar Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500.
Kiora Pharmaceuticals' return on equity of 30.24% beat Monopar Therapeutics' return on equity.
Monopar Therapeutics currently has a consensus target price of $2.00, suggesting a potential upside of 196.25%. Given Monopar Therapeutics' higher probable upside, analysts plainly believe Monopar Therapeutics is more favorable than Kiora Pharmaceuticals.
Monopar Therapeutics received 27 more outperform votes than Kiora Pharmaceuticals when rated by MarketBeat users. Likewise, 70.91% of users gave Monopar Therapeutics an outperform vote while only 66.67% of users gave Kiora Pharmaceuticals an outperform vote.
1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 41.6% of Monopar Therapeutics shares are owned by company insiders. Comparatively, 1.5% of Kiora Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Monopar Therapeutics beats Kiora Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
Get Monopar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Monopar Therapeutics Competitors List
Related Companies and Tools
